Document and Entity Information
Document and Entity Information | Mar. 31, 2022 |
Cover [Abstract] | |
Amendment Flag | true |
Entity Central Index Key | 0001492674 |
Document Type | 8-K/A |
Document Period End Date | Mar. 31, 2022 |
Entity Registrant Name | T2 BIOSYSTEMS, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-36571 |
Entity Tax Identification Number | 20-4827488 |
Entity Address, Address Line One | 101 Hartwell Avenue |
Entity Address, City or Town | Lexington |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02421 |
City Area Code | (781) |
Local Phone Number | 761-4646 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common stock, par value $0.001 per share |
Trading Symbol | TTOO |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Description | This Amendment No. 1 to the Current Report on Form 8-K amends Item 1.01 of the Current Report on Form 8-K filed on April 1, 2022 (the “Original Form 8-K”) solely to correct a typographical error in the description of the amount of funding being provided to T2 Biosystems, Inc., a Delaware corporation (the “Company”) by the Biomedical Advanced Research and Development Authority (“BARDA”) under Option 2B of the existing multiple-year cost-share contract between BARDA and the Company (the “BARDA Contract”). The Original Form 8-K incorrectly stated the amount as $44 million. The correct amount is $4.4. million. No other changes have been made to the Original Form 8-K. |